BioCatalystWatch
AVXLWorkspace / AVXL / OverviewCompany library
ANAVEX LIFE SCIENCES CORP. logo

ANAVEX LIFE SCIENCES CORP.

ANAVEX LIFE SCIENCES CORP. (AVXL)

Website

Price
Market cap
Next catalystNovember 2026 — FDA meeting on pediatric inclusionBlarcamesine — planned adult Rett study ANAVEX2-73-RS-005 · Regulatory meetingSEC filing ↗
Cash

Chart & Events

Candle interval

Core Clinical

Blarcamesine

SIGMAR1 (sigma-1 receptor) × Muscarinic receptors

PreINDP1P2FilingApproved
Upcoming / outlook

  • Timing and evidence

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

Blarcamesine

SIGMAR1 (sigma-1 receptor) × Muscarinic receptors

PreINDP1P2FilingApproved
Upcoming / outlook

  • Timing and evidence

Other pipelines

Oral Solid ANAVEX®3-71 (AF710B)

SIGMAR1 (sigma-1 receptor) × M1 muscarinic receptor

Oral Solid ANAVEX®3-71 (AF710B)

SIGMAR1 (sigma-1 receptor) × M1 muscarinic receptor

PreINDP1P2P3FilingApproved
Blarcamesine

SIGMAR1 (sigma-1 receptor) × Muscarinic receptors

PreINDP1P2P3FilingApproved

History / paused

SIGMAR1 (sigma-1 receptor) × M1 muscarinic receptor

PreINDP1P2P3FilingApproved
Blarcamesine

SIGMAR1 (sigma-1 receptor) × Muscarinic receptors

PreINDP1P2P3FilingApproved
Blarcamesine

SIGMAR1 (sigma-1 receptor) × Muscarinic receptors

PreINDP1P2P3FilingApproved
Blarcamesine

SIGMAR1 (sigma-1 receptor) × Muscarinic receptors

PreINDP1P2P3FilingApproved

Financial position

Short-term investments

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Source and basis

Source and basis

Source and basis

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

AVXL PR & News

PR & News

AVXL SEC archive